Extrait

Twenty patients with verified high risk breast cancer will be included in the study. Patients will receive three cycles of docetaxel followed by three cycles of CEF for their adjuvant treatment. The phenotype of CYP3A and the genotype of CYP3A5 and MDR1 will be assessed. Also the effect of docetaxel in the activity of CYP3A will be measured by peroral midazolam. Primary Object: The primary object of this study is to define, if it is possible to predict the clearance and/ or toxicity of docetaxel by assessing - activity of CYP3A4 by midazolam test (CYP3A4 phenotype) - CYP3A5 genotype - MDR1 genotype Secondary object: The secondary object of this study is to define whether the treatment with docetaxel alters the activity of CYP3A4 enzyme in previously untreated breast cancer patients.

Critère d'inclusion

• CYP3A Phenotyping ,CYP3A5 and MDR1 Genotyping ,Docetaxel Toxicity ,Associations Between Genetic Data and Docetaxel Toxicity

Liens

• nct
• ictrp